Chronic lymphocytic leukemia
|Chronic lymphocytic leukemia|
|Other names||B-cell chronic lymphocytic leukemia (B-CLL)|
|Peripheral blood smear showing CLL cells|
|Specialty||Hematology and oncology|
Later: Non-painful lymph nodes swelling, feeling tired, fever, weight loss
|Usual onset||Older than 50|
|Risk factors||Family history, Agent Orange, certain insecticides|
|Diagnostic method||Blood tests|
|Differential diagnosis||Mononucleosis, hairy cell leukemia, acute lymphocytic leukemia, persistent polyclonal B-cell lymphocytosis|
|Treatment||Watchful waiting, chemotherapy, immunotherapy|
|Prognosis||Five-year survival ~83% (US)|
Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur. Enlargement of the spleen and low red blood cells (anemia) may also occur. It typically worsens gradually over years.
Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.
Early-stage CLL in asymptomatic cases responds better to careful observation, as there is no evidence that early intervention treatment can alter the course of the disease. Immune defects occur early in the course of CLL and these increase the risk of developing serious infection, which should be treated appropriately with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. As of 2019 ibrutinib is often the initial medication recommended. The medications fludarabine, cyclophosphamide, and rituximab were previously the initial treatment in those who are otherwise healthy.
CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Men are diagnosed around twice as often as women (6.8 to 3.5 ratio). It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.
Signs and symptoms
Most people are diagnosed as having CLL based on the result of a routine blood test that shows a high white blood cell count, specifically a large increase in the number of circulating lymphocytes. These people generally have no symptoms. Less commonly, CLL may present with enlarged lymph nodes. This is referred to as small lymphocytic lymphoma. Less commonly the disease comes to light only after the cancerous cells overwhelm the bone marrow resulting in low red blood cells, neutrophils, or platelets. Or there is fever, night sweats, weight loss, and the person feels tired.
CLL can be grouped with Small lymphocytic lymphoma (SLL) as one disease with two clinical presentations. Wherein, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. CLLs are, in virtually all cases, preceded by a particular subtype of monoclonal B-cell lymphocytosis (MBL). This subtype, termed chronic lymphocytic leukemia-type MBL (CLL-type MBL) is an asymptomatic, indolent, and chronic disorder in which individuals exhibit a mild increase in the number of circulating B-cell lymphocytes. These B-cells are abnormal: they are monoclonal, i.e. produced by a single ancestral B-cell, and have some of the same cell marker proteins, chromosome abnormalities, and gene mutations found in CLL. CLL/SLL MBL consist of two groups: low-count CLL/SLL MBL has monoclonal B-cell blood counts of <0.5x9 cells/liter (i.e. 0.5x9/L) while high-count CLL/SLL MBL has blood monoclonal B-cell counts ≥0.5x9/L but <5x109/L. Individuals with blood counts of these monoclonal B-cells >5x9/L are diagnosed as having CLL. Low-count CLL/SLL MBL rarely if ever progresses to CLL while high-count CLL/SLL MBL does so at a rate of 1-2% per year. Thus, CLL may present in individuals with a long history of having high-count CLL/SLL MBL. There is no established treatment for these individuals except monitoring for development of the disorder's various complications (see treatment of MBL complications) and for their progression to CLL.
Complications include a low level of antibodies in the bloodstream (hypogammaglobulinemia) leading to recurrent infection, warm autoimmune hemolytic anemia in 10–15% of patients, and bone marrow failure. Chronic lymphocytic leukemia may also transform into Richter's syndrome, the development of fast-growing diffuse large B cell lymphoma, prolymphocytic leukemia, Hodgkin's lymphoma, or acute leukemia in some patients. Its incidence is estimated to be around 5% in patients with CLL.
Gastrointestinal (GI) involvement can rarely occur with chronic lymphocytic leukemia. Some of the reported manifestations include intussusception, small intestinal bacterial contamination, colitis, and others. Usually, GI complications with CLL occur after Richter transformation. Two cases to date have been reported of GI involvement in chronic lymphocytic leukemia without Richter's transformation.
CLL can be caused by many different genetic mutations, the most common being deletions in the 13q14.3 region, (seen in 50% of CLL cases), as well as trisomy in chromosome 12 (seen in 20% of cases), other deletions (i.e., in 11q22-23, 17p13, or 16q21 regions), and less commonly, translocations (for example, involving the 13q14 region). CLL can also be caused by a number of epigenetic changes, which can be classified into 3 different methylation subgroups (naïve B-cell-like, memory B-cell-like, and intermediate). Some relevant genetic mutations may be inherited. Since there is no one single mutation that causes CLL in all cases, an individual’s susceptibility may be impacted when multiple mutations that increase the risk of CLL are co-inherited. Up until 2014, very few of these mutations or significant “risk alleles” had been identified. Men are about twice as likely to get CLL as women, and risk increases with age. It is relatively rare among Asians. Exposure to Agent Orange increases the risk of CLL, and exposure to hepatitis C virus may increase the risk. There is no clear association between ionizing radiation exposure and the risk of developing CLL. Blood transfusions have been ruled out as a risk factor.
CLL is usually first suspected by a diagnosis of lymphocytosis, an increase in a type of white blood cell, on a complete blood count test. This frequently is an incidental finding on a routine physician visit. Most often the lymphocyte count is greater than 5000 cells per microliter (µl) of blood, but can be much higher. The presence of lymphocytosis in an elderly individual should raise strong suspicion for CLL, and a confirmatory diagnostic test, in particular flow cytometry, should be performed unless clinically unnecessary.
A peripheral blood smear showing an abundance of damaged cells known as "smudge cells" or "basket cells" can also indicate the presence of the disease (smudge cells are due to cancer cells lacking in vimentin, a cytoskeletal protein).:1899
The diagnosis of CLL is based on the demonstration of an abnormal population of B lymphocytes in the blood, bone marrow, or tissues that display an unusual but characteristic pattern of molecules on the cell surface. This atypical molecular pattern includes the coexpression of cell surface markers clusters of differentiation 5 (CD5) and 23. In addition, all the CLL cells within one individual are clonal, that is, genetically identical. In practice, this is inferred by the detection of only one of the mutually exclusive antibody light chains, kappa or lambda, on the entire population of the abnormal B cells. Normal B lymphocytes consist of a stew of different antibody-producing cells, resulting in a mixture of both kappa- and lambda-expressing cells. The lack of the normal distribution of these B cells is one basis for demonstrating clonality, the key element for establishing a diagnosis of any B cell malignancy (B cell non-Hodgkin lymphoma).
The combination of the microscopic examination of the peripheral blood and analysis of the lymphocytes by flow cytometry to confirm clonality and marker molecule expression is needed to establish the diagnosis of CLL. Both are easily accomplished on a small amount of blood. A flow cytometer instrument can examine the expression of molecules on individual cells in fluids. This requires the use of specific antibodies to marker molecules with fluorescent tags recognized by the instrument. In CLL, the lymphocytes are genetically clonal, of the B cell lineage (expressing marker molecules clusters of differentiation 19 and 20), and characteristically express the marker molecules CD5 and CD23. These B cells resemble normal lymphocytes under the microscope, although slightly smaller, and are fragile when smeared onto a glass slide, giving rise to many broken cells, which are called "smudge" or "smear" cells.
The Matutes's CLL score allows the identification of a homogeneous subgroup of classical CLL, that differs from atypical/mixed CLL for the five markers' expression (CD5, CD23, FMC7, CD22, and immunoglobulin light chain) Matutes's CLL scoring system is very helpful for the differential diagnosis between classical CLL and the other B cell chronic lymphoproliferative disorders, but not for the immunological distinction between mixed/atypical CLL and mantle cell lymphoma (MCL malignant B cells). Discrimination between CLL and MCL can be improved by adding non-routine markers such as CD54 and CD200. Among routine markers, the most discriminating feature is the CD20/CD23 mean fluorescence intensity ratio. In contrast, FMC7 expression can surprisingly be misleading for borderline cases.
Staging, determining the extent of the disease, is done with the Rai staging system or the Binet classification (see details) and is based primarily on the presence of a low platelet or red cell count. Early-stage disease does not need to be treated. CLL and SLL are considered the same underlying disease, just with different appearances.:1441
- Stage 0: characterized by absolute lymphocytosis (>15,000/mm3) without lymphadenopathy, hepatosplenomegaly, anemia, or thrombocytopenia
- Stage I: characterized by absolute lymphocytosis with lymphadenopathy without hepatosplenomegaly, anemia, or thrombocytopenia
- Stage II: characterized by absolute lymphocytosis with either hepatomegaly or splenomegaly with or without lymphadenopathy
- Stage III: characterized by absolute lymphocytosis and anemia (hemoglobin <11 g/dL) with or without lymphadenopathy, hepatomegaly, or splenomegaly
- Stage IV: characterized by absolute lymphocytosis and thrombocytopenia (<100,000/mm3) with or without lymphadenopathy, hepatomegaly, splenomegaly, or anemia
- Clinical stage A: characterized by no anemia or thrombocytopenia and fewer than three areas of lymphoid involvement (Rai stages 0, I, and II)
- Clinical stage B: characterized by no anemia or thrombocytopenia with three or more areas of lymphoid involvement (Rai stages I and II)
- Clinical stage C: characterized by anemia and/or thrombocytopenia regardless of the number of areas of lymphoid enlargement (Rai stages III and IV)
Array-based karyotyping is a cost-effective alternative to FISH for detecting chromosomal abnormalities in CLL. Several clinical validation studies have shown >95% concordance with the standard CLL FISH panel.
In the past, cases with similar microscopic appearance in the blood but with a T cell phenotype were referred to as T-cell CLL. However, these are now recognized as a separate disease group and are currently classified as T-cell prolymphocytic leukemias.
CLL should not be confused with acute lymphoblastic leukemia, a highly aggressive leukemia most commonly diagnosed in children, and highly treatable in the pediatric setting.
|Lymphoid disorders that can present as chronic leukemia and can be confused with typical B-cell chronic lymphoid leukemia|
|Splenic marginal zone lymphoma|
|Nodal marginal zone B cell lymphoma|
|Mantle cell lymphoma|
|Hairy cell leukemia|
|Prolymphocytic leukemia (B cell or T cell)|
|Smoldering adult T cell leukemia/lymphoma|
Hematologic disorders that may resemble CLL in their clinical presentation, behavior, and microscopic appearance include mantle cell lymphoma, marginal zone lymphoma, B cell prolymphocytic leukemia, and lymphoplasmacytic lymphoma.
- B cell prolymphocytic leukemia, a related, but more aggressive disorder, has cells with similar phenotype, but are significantly larger than normal lymphocytes and have a prominent nucleolus. The distinction is important as the prognosis and therapy differ from CLL.
- Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the microscope (hairy cell leukemia cells have delicate, hair-like projections on their surfaces) and unique marker molecule expression.
All the B cell malignancies of the blood and bone marrow can be differentiated from one another by the combination of cellular microscopic morphology, marker molecule expression, and specific tumor-associated gene defects. This is best accomplished by evaluation of the patient's blood, bone marrow, and occasionally lymph node cells by a pathologist with specific training in blood disorders. A flow cytometer is necessary for cell marker analysis, and the detection of genetic problems in the cells may require visualizing the DNA changes with fluorescent probes by FISH.
CLL is treated by chemotherapy, radiation therapy, biological therapy, or bone marrow transplantation. Symptoms are sometimes treated surgically (splenectomy – removal of enlarged spleen) or by radiation therapy ("de-bulking" swollen lymph nodes).
Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease, and even with the preference and experience of the health care practitioner. Any of dozens of agents may be used for CLL therapy.
Decision to treat
While it is generally considered incurable, CLL progresses slowly in most cases. Many people with CLL lead normal and active lives for many years—in some cases for decades. Because of its slow onset, early-stage CLL is, in general, not treated since it is believed that early CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time to detect any change in the disease pattern.
The decision to start CLL treatment is taken when the person's symptoms or blood counts indicate that the disease has progressed to a point where it may affect quality of life.
Clinical "staging systems" such as the Rai four-stage system and the Binet classification can help to determine when and how to treat the patient.
Determining when to start treatment and by what means is often difficult; no survival advantage is seen in treating the disease very early. The National Cancer Institute Working Group has issued guidelines for treatment, with specific markers that should be met before it is initiated.
Combination chemotherapy regimens are effective in both newly diagnosed and relapsed CLL. Combinations of fludarabine with alkylating agents (cyclophosphamide) produce higher response rates and a longer progression-free survival than single agents:
- FC (fludarabine with cyclophosphamide)
- FR (fludarabine with rituximab)
- FCR (fludarabine, cyclophosphamide, and rituximab)
- CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Although the purine analogue fludarabine was shown to give superior response rates to chlorambucil as primary therapy, no evidence shows early use of fludarabine improves overall survival, and some clinicians prefer to reserve fludarabine for relapsed disease.
Chemoimmunotherapy with FCR has shown to improve response rates, progression-free survival, and overall survival in a large randomized trial in CLL patients selected for good physical fitness. This has been the first clinical trial demonstrating that the choice of a first-line therapy can improve the overall survival of patients with CLL.
Targeted therapy attacks cancer cells at a specific target, with the aim of not harming normal cells. Targeted drugs used in CLL include venetoclax (a Bcl-2 inhibitor), ibrutinib (a Bruton's tyrosine kinase inhibitor), idelalisib and duvelisib (inhibitors of some forms of the enzyme phosphoinositide 3-kinase), as well as monoclonal antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab).
Stem cell transplantation
Autologous stem cell transplantation, using the recipient's own cells, is not curative.:1458 Younger individuals, if at high risk for dying from CLL, may consider allogeneic hematopoietic stem cell transplantation (HSCT). Myeloablative (bone marrow killing) forms of allogeneic stem cell transplantation, a high-risk treatment using blood cells from a healthy donor, may be curative, but treatment-related toxicity is significant.:1458 An intermediate level, called reduced-intensity conditioning allogeneic stem cell transplantation, may be better tolerated by older or frail patients.
"Refractory" CLL is a disease that no longer responds favorably to treatment. In this case, more aggressive therapies, including lenalidomide, flavopiridol, and bone marrow (stem cell) transplantation, are considered. The monoclonal antibody alemtuzumab (directed against CD52) may be used in patients with refractory, bone marrow-based disease.
Leukemia is rarely associated with pregnancy, affecting only about one in 10,000 pregnant women. Treatment for chronic lymphocytic leukemias can often be postponed until after the end of the pregnancy. If treatment is necessary, then giving chemotherapy during the second or third trimesters is less likely to result in pregnancy loss or birth defects than treatment during the first trimester.
Prognosis can be affected by the type of genetic mutation that the person with CLL has. Some examples of genetic mutations and their prognoses are: mutations in the IGHV region are associated with a median overall survival (OS) of more than 20–25 years, while no mutations in this region is associated with a median OS of 8–10 years; deletion of chromosome 13q is associated with a median OS of 17 years; and trisomy of chromosome 12, as well as deletion of chromosome 11q, is associated with a median OS of 9–11 years. While prognosis is highly variable and dependent on various factors including these mutations, the average 5-year relative survival is 86.1%. Telomere length has been suggested to be a valuable prognostic indicator of survival.
CLL is primarily a disease of older adults, with a median age of 70 years at the time of diagnosis. Though less common, CLL sometimes affects people between 30 and 39 years of age.[medical citation needed] The incidence of CLL increases very quickly with increasing age.[medical citation needed]
In the United States during 2014, about 15,720 new cases are expected to be diagnosed, and 4,600 patients are expected to die from CLL. Because of the prolonged survival, which was typically about 10 years in past decades, but which can extend to a normal life expectancy, the prevalence (number of people living with the disease) is much higher than the incidence (new diagnoses). CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases. Approximately 3,200 people were diagnosed with the disease in 2011.
In Western populations, subclinical "disease" can be identified in 3.5% of normal adults, and in up to 8% of individuals over the age of 70. That is, small clones of B cells with the characteristic CLL phenotype can be identified in many healthy elderly persons. The clinical significance of these cells is unknown.
In contrast, CLL is rare in Asian countries, such as Japan, China, and Korea, accounting for less than 10% of all leukemias in those regions.:1432 A low incidence is seen in Japanese immigrants to the US, and in African and Asian immigrants to Israel.
Rates of CLL are somewhat elevated in people exposed to certain chemicals. Under U.S. Department of Veterans' Affairs regulations, Vietnam veterans who served in-country or in the inland waterways of Vietnam and who later develop CLL are presumed to have contracted it from exposure to Agent Orange and may be entitled to compensation.
Research in 2008 is comparing different forms of bone marrow transplants to determine which patients are the best candidates and which approach is best in different situations.
|Wikinews has related news:|
Researchers at the Abramson Cancer Center of the University of Pennsylvania School of Medicine reported preliminary success in the use of gene therapy, through genetically modified T cells, to treat CLL. The findings, which were published in August 2011, were based on data from three patients who had modified T cells injected into their blood. The T cells had been modified to express genes that would allow the cells to proliferate in the body and destroy B cells including those causing the leukemia. Two patients went into remission, while the presence of leukemia in the third patient reduced by 70%.
One of the patients had been diagnosed with CLL for 13 years, and his treatment was failing before he participated in the clinical trial. One week after the T cells were injected, the leukemia cells in his blood had disappeared. The T cells were still found in the bloodstream of the patients six months after the procedure, meaning they would be able to fight the disease should leukemia cells return. This was the first time scientists "have used gene therapy to successfully destroy cancer tumors in patients with advanced disease".
Research is also investigating therapies targeting B cell receptor signalling. Syk inhibitor fostamatinib is in trials. The trial of a combination of ibrutinib and venetoclax had encouraging results in a small number of people.
- O'Brien S, Gribben JG (2008). Chronic Lymphocytic Leukemia. CRC Press. p. 19. ISBN 9781420068962.
- "Chronic Lymphocytic Leukemia Treatment". National Cancer Institute. 26 October 2017. Retrieved 19 December 2017.
- "Chronic Lymphocytic Leukemia - Cancer Stat Facts". seer.cancer.gov. Retrieved 20 December 2017.
- Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. (January 2017). "Chronic lymphocytic leukaemia". Nature Reviews. Disease Primers. 3: 16096. doi:10.1038/nrdp.2016.96. PMC 5336551. PMID 28102226.
- Ferri FF (2017). Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 750. ISBN 9780323529570.
- Vos, Theo; Allen, Christine; Arora, Megha; Barber, Ryan M.; Bhutta, Zulfiqar A.; Brown, Alexandria; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Z.; Coggeshall, Megan; Cornaby, Leslie; Dandona, Lalit; Dicker, Daniel J.; Dilegge, Tina; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Fleming, Tom; Forouzanfar, Mohammad H.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kawashima, Toana; et al. (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- Wang, Haidong; Naghavi, Mohsen; Allen, Christine; Barber, Ryan M.; Bhutta, Zulfiqar A.; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Zian; Coates, Matthew M.; Coggeshall, Megan; Dandona, Lalit; Dicker, Daniel J.; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Foreman, Kyle; Forouzanfar, Mohammad H.; Fraser, Maya S.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Huynh, Chantal; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kinfu, Yohannes; et al. (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- Boelens J, Lust S, Vanhoecke B, Offner F (February 2009). "Chronic lymphocytic leukaemia". Anticancer Research. 29 (2): 605–15. PMID 19331210.
- Hallek M, Shanafelt TD, Eichhorst B (April 2018). "Chronic lymphocytic leukaemia". Lancet. 391 (10129): 1524–1537. doi:10.1016/S0140-6736(18)30422-7. PMID 29477250. S2CID 3517733.
- Stilgenbauer, Stephan; Furman, Richard R.; Zent, Clive S. (2015-05-01). "Management of Chronic Lymphocytic Leukemia". American Society of Clinical Oncology Educational Book (35): 164–175. doi:10.14694/EdBook_AM.2015.35.164. ISSN 1548-8748. PMID 25993154.
- "Chronic Lymphocytic Leukemia Treatment". National Cancer Institute. 1 January 1980. Retrieved 19 February 2019.
- Hallek M (September 2017). "Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment". American Journal of Hematology. 92 (9): 946–965. doi:10.1002/ajh.24826. PMID 28782884.
- Grywalska, Ewelina; Zaborek, Monika; Łyczba, Jakub; Hrynkiewicz, Rafał; Bębnowska, Dominika; Becht, Rafał; Sosnowska-Pasiarska, Barbara; Smok-Kalwat, Jolanta; Pasiarski, Marcin; Góźdź, Stanisław; Roliński, Jacek (November 2020). "Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review". Cells. 9 (11): 2398. doi:10.3390/cells9112398. PMC 7693361. PMID 33147729.
- Rai, Kanti R.; Jain, Preetesh (March 2016). "Chronic lymphocytic leukemia (CLL)-Then and now". American Journal of Hematology. 91 (3): 330–340. doi:10.1002/ajh.24282. ISSN 1096-8652. PMID 26690614.
- Jaffe ES (January 2019). "Diagnosis and classification of lymphoma: Impact of technical advances". Seminars in Hematology. 56 (1): 30–36. doi:10.1053/j.seminhematol.2018.05.007. PMC 7394061. PMID 30573042.
- Angelillo P, Capasso A, Ghia P, Scarfò L (December 2018). "Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?". European Journal of Internal Medicine. 58: 2–6. doi:10.1016/j.ejim.2018.09.006. PMID 30268574.
- Tresckow JV, Eichhorst B, Bahlo J, Hallek M (January 2019). "The Treatment of Chronic Lymphatic Leukemia". Deutsches Ärzteblatt International. 116 (4): 41–46. doi:10.3238/arztebl.2019.0041. PMC 6415618. PMID 30855005.
- Choi SM, O'Malley DP (December 2018). "Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms". Annals of Diagnostic Pathology. 37: 67–74. doi:10.1016/j.anndiagpath.2018.09.011. PMID 30308438.
- Hallek M (September 2017). "Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment". American Journal of Hematology. 92 (9): 946–965. doi:10.1002/ajh.24826. PMID 28782884.
- Tsimberidou AM, Keating MJ (January 2005). "Richter syndrome: biology, incidence, and therapeutic strategies". Cancer. 103 (2): 216–28. doi:10.1002/cncr.20773. PMID 15578683. S2CID 21552054.
- Bitetto AM, Lamba G, Cadavid G, Shah D, Forlenza T, Rotatori F, Rafiyath SM. Colonic perforation secondary to chronic lymphocytic leukemia infiltration without Richter transformation. Leuk Lymphoma. 2011 May;52(5):930-3.
- WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow, Steven H.,, World Health Organization,, International Agency for Research on Cancer (Revised 4th ed.). Lyon. 2017. p. 219. ISBN 978-92-832-4494-3. OCLC 1011064243.CS1 maint: others (link)
- Sava, Georgina P.; Speedy, Helen E.; Houlston, Richard S. (January 2014). "Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis". Leukemia & Lymphoma. 55 (1): 160–167. doi:10.3109/10428194.2013.800197. ISSN 1029-2403. PMID 23647060. S2CID 207510537.
- Strati P, Jain N, O'Brien S (May 2018). "Chronic Lymphocytic Leukemia: Diagnosis and Treatment". Mayo Clinic Proceedings (Review). 93 (5): 651–664. doi:10.1016/j.mayocp.2018.03.002. PMID 29728204.
- Greer JP, Arber DA, Glader B, List AF, Means Jr RT, Paraskevas F, Rodgers GM, Foerster J, eds. (2014). Wintrobe's clinical hematology (Thirteenth ed.). Lippincott Williams & Wilkins. ISBN 978-1451172683.
- Bain, Barbara J. (2006). Blood Cells: A Practical Guide. Blackwell Publishing Limited. p. 439. ISBN 978-1-4051-4265-6.
- Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, Catovsky D (October 1994). "The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL". Leukemia. 8 (10): 1640–5. PMID 7523797.
- Deans JP, Polyak MJ (February 2008). "FMC7 is an epitope of CD20". Blood. 111 (4): 2492, author reply 2493–4. doi:10.1182/blood-2007-11-126243. PMID 18263793.
- Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, et al. (September 2009). "CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia". Leukemia Research. 33 (9): 1212–6. doi:10.1016/j.leukres.2009.01.017. PMID 19230971.
- Zare H, Bashashati A, Kridel R, Aghaeepour N, Haffari G, Connors JM, et al. (January 2012). "Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma". American Journal of Clinical Pathology. 137 (1): 75–85. doi:10.1309/AJCPMMLQ67YOMGEW. PMC 4090220. PMID 22180480.
- National Cancer Institute (January 1980). "Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage Information". Archived from the original on 17 October 2007. Retrieved 2007-09-04.
- Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U (2010). Williams Hematology (8th ed.). McGraw-Hill. ISBN 978-0071621519.
- Gale, Robert Peter; Rai, Kanti R., eds. (1987). Chronic lymphocytic leukemia : recent progress, future direction : proceedings of a Hyland Laboratories-UCLA symposium held in Napa, California, December 2–5, 1986. New York: Liss. ISBN 9780845126585.
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (August 1975). "Clinical staging of chronic lymphocytic leukemia". Blood. 46 (2): 219–34. doi:10.1182/blood.V184.108.40.206. PMID 1139039.
- Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. (July 1981). "A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis". Cancer. 48 (1): 198–206. doi:10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v. PMID 7237385.
- Lehmann S, Ogawa S, Raynaud SD, Sanada M, Nannya Y, Ticchioni M, et al. (March 2008). "Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia". Cancer. 112 (6): 1296–305. doi:10.1002/cncr.23270. PMID 18246537. S2CID 205651767.
- Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, et al. (January 2009). "Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia". The Journal of Molecular Diagnostics. 11 (1): 25–34. doi:10.2353/jmoldx.2009.080037. PMC 2607562. PMID 19074592.
- Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, et al. (January 2004). "Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations". Proceedings of the National Academy of Sciences of the United States of America. 101 (4): 1039–44. Bibcode:2004PNAS..101.1039S. doi:10.1073/pnas.0304717101. PMC 327147. PMID 14730057.
- Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM, et al. (February 2007). "Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays". Blood. 109 (3): 1202–10. doi:10.1182/blood-2006-07-034256. PMID 17053054.
- Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, et al. (September 2008). "Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia". The Journal of Molecular Diagnostics. 10 (5): 442–51. doi:10.2353/jmoldx.2008.080033. PMC 2518739. PMID 18687794.
- "T Cell Prolymphocytic Leukemia". AccessMedicine. Archived from the original on 2011-07-07. Retrieved 2009-02-04.
- Ascani S, Leoni P, Fraternali Orcioni G, Bearzi I, Piccioli M, Materazzi M, et al. (June 1999). "T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature". Annals of Oncology. 10 (6): 649–53. doi:10.1023/A:1008349422735. PMID 10442186.
- Kasper, Dennis L.; Fauci, Anthony S.; Hauser, Stephen L.; Longo, Dan L.; Larry Jameson, J.; Loscalzo, Joseph (17 April 2015). "Malignancies of Lymphoid Cells". Harrison's Principles of Internal Medicine (19 ed.). p. 695. ISBN 9780071802161.
- National Cancer Institute (January 1980). "Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage I, II, III, and IV Chronic Lymphocytic Leukemia". Archived from the original on 17 October 2007. Retrieved 2007-09-04.
- Janssens; et al. (2011). "Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients". Contemporary Oncology. 3 (3): 24–36.
- Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (June 1996). "National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment". Blood. 87 (12): 4990–7. doi:10.1182/blood.V87.12.4990.bloodjournal87124990. PMID 8652811.
- Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. (February 2006). "Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia". Blood. 107 (3): 885–91. doi:10.1182/blood-2005-06-2395. PMID 16219797.
- Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. (January 2003). "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)". Blood. 101 (1): 6–14. doi:10.1182/blood-2002-04-1258. PMID 12393429.
- Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. (June 2005). "Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia". Journal of Clinical Oncology. 23 (18): 4079–88. doi:10.1200/JCO.2005.12.051. PMID 15767648.
- Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. (December 2000). "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia". The New England Journal of Medicine. 343 (24): 1750–7. doi:10.1056/NEJM200012143432402. PMID 11114313.
- Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R (July 2006). Steurer M (ed.). "Purine antagonists for chronic lymphocytic leukaemia". The Cochrane Database of Systematic Reviews. 3 (3): CD004270. doi:10.1002/14651858.CD004270.pub2. PMID 16856041.
- Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. (October 2010). "Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial". Lancet. 376 (9747): 1164–74. doi:10.1016/S0140-6736(10)61381-5. PMID 20888994. S2CID 28834830.
- Khan M, Siddiqi T (December 2018). "Targeted Therapies in CLL: Monotherapy Versus Combination Approaches". Current Hematologic Malignancy Reports. 13 (6): 525–533. doi:10.1007/s11899-018-0481-7. PMID 30535947. S2CID 54473182.
- Gribben JG (January 2009). "Stem cell transplantation in chronic lymphocytic leukemia". Biology of Blood and Marrow Transplantation. 15 (1 Suppl): 53–8. doi:10.1016/j.bbmt.2008.10.022. PMC 2668540. PMID 19147079.
- Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, et al. (May 2003). "Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning". Leukemia. 17 (5): 841–8. doi:10.1038/sj.leu.2402905. PMID 12750695.
- National Cancer Institute (January 1980). "Chronic Lymphocytic Leukemia (PDQ) Treatment: Refractory Chronic Lymphocytic Leukemia". Archived from the original on 17 October 2007. Retrieved 2007-09-04.
- Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. (May 2002). "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study". Blood. 99 (10): 3554–61. doi:10.1182/blood.V99.10.3554. PMID 11986207.
- Shapira T, Pereg D, Lishner M (September 2008). "How I treat acute and chronic leukemia in pregnancy". Blood Reviews. 22 (5): 247–59. doi:10.1016/j.blre.2008.03.006. PMID 18472198.
- Bosch, Francesc; Dalla-Favera, Riccardo (November 2019). "Chronic lymphocytic leukaemia: from genetics to treatment". Nature Reviews. Clinical Oncology. 16 (11): 684–701. doi:10.1038/s41571-019-0239-8. ISSN 1759-4782. PMID 31278397. S2CID 195804409.
- "Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version - National Cancer Institute". www.cancer.gov. 2020-10-09. Retrieved 2020-12-07.
- "Chronic Lymphocytic Leukemia - Cancer Stat Facts". SEER. Retrieved 2020-12-07.
- Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. (June 2009). "Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia". Leukemia. 23 (6): 1062–72. doi:10.1038/leu.2008.399. hdl:2434/663837. PMID 19340005.
- Shanshal M, Haddad RY (April 2012). "Chronic lymphocytic leukemia". Disease-A-Month. 58 (4): 153–67. doi:10.1016/j.disamonth.2012.01.009. PMID 22449365.
- National Cancer Institute (January 1980). "General Information About Chronic Lymphocytic Leukemia". Retrieved 2007-09-04.
- "Chronic lymphocytic leukaemia (CLL) statistics". Cancer Research UK. Retrieved 27 October 2014.
- Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, et al. (July 2002). "Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts". Blood. 100 (2): 635–9. doi:10.1182/blood.V100.2.635. PMID 12091358.
- Turgeon, Mary Louise (2005). Clinical hematology: theory and procedures. Hagerstown, MD: Lippincott Williams & Wilkins. p. 283. ISBN 978-0-7817-5007-3.
Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and Lymphoid Tissues. 2001, p. 2001.)CS1 maint: uses authors parameter (link)
- Auer H (August 10, 2011). "Genetically Modified "Serial Killer" T Cells Obliterate Tumors in Patients with Chronic Lymphocytic Leukemia, Penn Researchers Report". University of Pennsylvania School of Medicine. Retrieved August 12, 2011.
- Porter DL, Levine BL, Kalos M, Bagg A, June CH (August 2011). "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia". The New England Journal of Medicine. 365 (8): 725–33. doi:10.1056/NEJMoa1103849. PMC 3387277. PMID 21830940.
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (August 2011). "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia". Science Translational Medicine. 3 (95): 95ra73. doi:10.1126/scitranslmed.3002842. PMC 3393096. PMID 21832238.
- Palca J (August 11, 2011). "Gene Therapy Advance Trains Immune System To Fight Leukemia". NPR. Retrieved August 12, 2011.
- Bazell R (August 10, 2011). "New leukemia treatment exceeds 'wildest expectations'". NBC News. Retrieved August 12, 2011.
- DeNoon DJ (August 10, 2011). "Gene Therapy Cures Adult Leukemia". WebMD. Retrieved August 12, 2011.
- Beasly D (August 10, 2011). "Gene therapy shown to destroy leukemia tumors". Reuters. Retrieved August 12, 2011.
- ten Hacken E, Burger JA (December 2014). "Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies". Pharmacology & Therapeutics. 144 (3): 338–48. doi:10.1016/j.pharmthera.2014.07.003. PMID 25050922.
- Munir T, Rawstron A, Brock K, Vicente S, Yates F, Bishop R, et al. (2017-12-07). "Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy". Blood. 130 (Suppl 1): 428.
- Chronic Lymphocytic Leukemia at American Cancer Society
- General information about CLL from the US National Cancer Institute
- Cancer.Net: Chronic Lymphocytic Leukemia